Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE.

J Clin Lipidol. 2019 May - Jun;13(3):374-392. doi: 10.1016/j.jacl.2019.04.010. Epub 2019 May 17.

PMID:
31147269
2.

Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis.

Zheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins WSA, Doris MK, White AC, Timmers NKLM, Hjortnaes J, Rogers MA, Aikawa E, Arsenault BJ, Witztum JL, Newby DE, Koschinsky ML, Fayad ZA, Stroes ESG, Boekholdt SM, Dweck MR.

J Am Coll Cardiol. 2019 May 7;73(17):2150-2162. doi: 10.1016/j.jacc.2019.01.070.

3.

New Frontiers in Lp(a)-Targeted Therapies.

Borrelli MJ, Youssef A, Boffa MB, Koschinsky ML.

Trends Pharmacol Sci. 2019 Mar;40(3):212-225. doi: 10.1016/j.tips.2019.01.004. Epub 2019 Feb 4. Review.

PMID:
30732864
4.

Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease.

Boffa MB, Koschinsky ML.

Nat Rev Cardiol. 2019 May;16(5):305-318. doi: 10.1038/s41569-018-0153-2. Review.

PMID:
30675027
5.

JCL roundtable-Lipoprotein(a): The emerging risk factor.

Marcovina SM, Moriarty PM, Koschinsky ML, Guyton JR.

J Clin Lipidol. 2018 Nov - Dec;12(6):1335-1345. doi: 10.1016/j.jacl.2018.11.003. Review.

PMID:
30527801
6.

Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal.

Boffa MB, Stranges S, Klar N, Moriarty PM, Watts GF, Koschinsky ML.

J Clin Lipidol. 2018 Nov - Dec;12(6):1358-1366. doi: 10.1016/j.jacl.2018.08.012. Epub 2018 Sep 11. Review.

PMID:
30316749
7.

Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells.

Romagnuolo R, DeMarco K, Scipione CA, Boffa MB, Koschinsky ML.

Thromb Res. 2018 Sep;169:1-7. doi: 10.1016/j.thromres.2018.07.002. Epub 2018 Jul 4.

PMID:
29990619
8.

Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins αMβ2 and αVβ3.

Romagnuolo R, Scipione CA, Bazzi ZA, Boffa MB, Koschinsky ML.

Atherosclerosis. 2018 Aug;275:11-21. doi: 10.1016/j.atherosclerosis.2018.05.029. Epub 2018 May 17.

PMID:
29852400
9.

The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?

Boffa MB, Koschinsky ML.

Curr Opin Lipidol. 2018 Jun;29(3):259-267. doi: 10.1097/MOL.0000000000000499.

PMID:
29528858
10.

Therapeutic Lowering of Lipoprotein(a): A Role for Pharmacogenetics?

Boffa MB, Koschinsky ML.

Circ Genom Precis Med. 2018 Feb;11(2):e002052. doi: 10.1161/CIRCGEN.118.002052. No abstract available.

PMID:
29449330
11.

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L.

J Am Coll Cardiol. 2018 Jan 16;71(2):177-192. doi: 10.1016/j.jacc.2017.11.014. Review.

12.

Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.

Scipione CA, Koschinsky ML, Boffa MB.

Crit Rev Clin Lab Sci. 2018 Jan;55(1):33-54. doi: 10.1080/10408363.2017.1415866. Epub 2017 Dec 20. Review.

PMID:
29262744
13.

Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach.

Paquet M, Cerasuolo JO, Thorburn V, Fridman S, Alsubaie R, Lopes RD, Cipriano LE, Salamone P, Melling CWJ, Khan AR, Sedeño L, Fang J, Drangova M, Montero-Odasso M, Mandzia J, Khaw AV, Racosta JM, Paturel J, Samoilov L, Stirling D, Balint B, Jaremek V, Koschinsky ML, Boffa MB, Summers K, Ibañez A, Mrkobrada M, Saposnik G, Kimpinski K, Whitehead SN, Sposato LA.

J Stroke Cerebrovasc Dis. 2018 Mar;27(3):606-619. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.038. Epub 2017 Nov 13.

PMID:
29141778
14.

The renaissance of lipoprotein(a): Brave new world for preventive cardiology?

Ellis KL, Boffa MB, Sahebkar A, Koschinsky ML, Watts GF.

Prog Lipid Res. 2017 Oct;68:57-82. doi: 10.1016/j.plipres.2017.09.001. Epub 2017 Sep 6. Review.

PMID:
28888913
15.

Pathobiology of Lp(a) in calcific aortic valve disease.

Mathieu P, Arsenault BJ, Boulanger MC, Bossé Y, Koschinsky ML.

Expert Rev Cardiovasc Ther. 2017 Oct;15(10):797-807. doi: 10.1080/14779072.2017.1367286. Epub 2017 Aug 24. Review.

PMID:
28816078
16.

Plasminogen promotes cholesterol efflux by the ABCA1 pathway.

Pamir N, Hutchins PM, Ronsein GE, Wei H, Tang C, Das R, Vaisar T, Plow E, Schuster V, Koschinsky ML, Reardon CA, Weinberg R, Dichek DA, Marcovina S, Getz GS, Heinecke JW.

JCI Insight. 2017 Aug 3;2(15). pii: 92176. doi: 10.1172/jci.insight.92176. eCollection 2017 Aug 3.

17.

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.

Romagnuolo R, Scipione CA, Marcovina SM, Gemin M, Seidah NG, Boffa MB, Koschinsky ML.

PLoS One. 2017 Jul 27;12(7):e0180869. doi: 10.1371/journal.pone.0180869. eCollection 2017.

18.

Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a).

Scipione CA, McAiney JT, Simard DJ, Bazzi ZA, Gemin M, Romagnuolo R, Macrae FL, Ariëns RA, Hegele RA, Auld J, Gauld JW, Boffa MB, Koschinsky ML.

J Thromb Haemost. 2017 Sep;15(9):1834-1844. doi: 10.1111/jth.13759. Epub 2017 Jul 31.

19.

OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway.

Nsaibia MJ, Boulanger MC, Bouchareb R, Mkannez G, Le Quang K, Hadji F, Argaud D, Dahou A, Bossé Y, Koschinsky ML, Pibarot P, Arsenault BJ, Marette A, Mathieu P.

Cardiovasc Res. 2017 Sep 1;113(11):1351-1363. doi: 10.1093/cvr/cvx089.

20.

Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles.

Oliveira C, Fournier C, Descamps V, Morel V, Scipione CA, Romagnuolo R, Koschinsky ML, Boullier A, Marcelo P, Domon JM, Brochot E, Duverlie G, Francois C, Castelain S, Helle F.

Hepatology. 2017 Jun;65(6):1851-1864. doi: 10.1002/hep.29096. Epub 2017 Apr 28.

21.

Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.

van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LA, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ES.

Circulation. 2016 Aug 23;134(8):611-24. doi: 10.1161/CIRCULATIONAHA.116.020838. Epub 2016 Aug 5.

22.

Activation of liver X receptor attenuates lysophosphatidylcholine-induced IL-8 expression in endothelial cells via the NF-κB pathway and SUMOylation.

Bi X, Song J, Gao J, Zhao J, Wang M, Scipione CA, Koschinsky ML, Wang ZV, Xu S, Fu G.

J Cell Mol Med. 2016 Dec;20(12):2249-2258. doi: 10.1111/jcmm.12903. Epub 2016 Aug 4.

23.

Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Boffa MB, Koschinsky ML.

J Lipid Res. 2016 May;57(5):745-57. doi: 10.1194/jlr.R060582. Epub 2015 Dec 8. Review.

24.

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).

Scipione CA, Sayegh SE, Romagnuolo R, Tsimikas S, Marcovina SM, Boffa MB, Koschinsky ML.

J Lipid Res. 2015 Dec;56(12):2273-85. doi: 10.1194/jlr.M060210. Epub 2015 Oct 16.

25.

Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve.

Bouchareb R, Mahmut A, Nsaibia MJ, Boulanger MC, Dahou A, Lépine JL, Laflamme MH, Hadji F, Couture C, Trahan S, Pagé S, Bossé Y, Pibarot P, Scipione CA, Romagnuolo R, Koschinsky ML, Arsenault BJ, Marette A, Mathieu P.

Circulation. 2015 Aug 25;132(8):677-90. doi: 10.1161/CIRCULATIONAHA.115.016757. Epub 2015 Jul 29.

PMID:
26224810
26.

Pro-inflammatory cytokines reduce human TAFI expression via tristetraprolin-mediated mRNA destabilisation and decreased binding of HuR.

Komnenov D, Scipione CA, Bazzi ZA, Garabon JJ, Koschinsky ML, Boffa MB.

Thromb Haemost. 2015 Aug;114(2):337-49. doi: 10.1160/TH14-08-0653. Epub 2015 Jun 11.

PMID:
26062599
27.

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.

Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML.

J Biol Chem. 2015 May 1;290(18):11649-62. doi: 10.1074/jbc.M114.611988. Epub 2015 Mar 16.

28.

Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum.

Koschinsky ML, Boffa MB.

Endocrinol Metab Clin North Am. 2014 Dec;43(4):949-62. doi: 10.1016/j.ecl.2014.08.002. Review.

PMID:
25432390
29.

Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).

Romagnuolo R, Marcovina SM, Boffa MB, Koschinsky ML.

J Lipid Res. 2014 Apr;55(4):625-34. doi: 10.1194/jlr.M036566. Epub 2014 Jan 29.

30.

Screening for and management of elevated Lp(a).

Boffa MB, Koschinsky ML.

Curr Cardiol Rep. 2013 Nov;15(11):417. doi: 10.1007/s11886-013-0417-8. Review.

PMID:
24057771
31.

Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Boffa MB, Koschinsky ML.

Curr Atheroscler Rep. 2013 Oct;15(10):360. doi: 10.1007/s11883-013-0360-6. Review.

PMID:
23990263
32.

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

Leibundgut G, Scipione C, Yin H, Schneider M, Boffa MB, Green S, Yang X, Dennis E, Witztum JL, Koschinsky ML, Tsimikas S.

J Lipid Res. 2013 Oct;54(10):2815-30. doi: 10.1194/jlr.M040733. Epub 2013 Jul 4.

33.

Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms.

Riches K, Franklin L, Maqbool A, Peckham M, Adams M, Bond J, Warburton P, Feric NT, Koschinsky ML, O'Regan DJ, Ball SG, Turner NA, Porter KE.

Int J Biochem Cell Biol. 2013 Aug;45(8):1776-83. doi: 10.1016/j.biocel.2013.05.021. Epub 2013 May 31.

34.

The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity.

Lin JH, Novakovic D, Rizzo CM, Zagorac B, Garand M, Filipieva A, Koschinsky ML, Boffa MB.

Thromb Haemost. 2013 Jun;109(6):1033-44. doi: 10.1160/TH12-09-0668. Epub 2013 Apr 18.

PMID:
23595589
35.

Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone.

Garand M, Lin JH, Zagorac B, Koschinsky ML, Boffa MB.

Blood Coagul Fibrinolysis. 2013 Jun;24(4):393-404. doi: 10.1097/MBC.0b013e32835d543a.

PMID:
23429253
36.

Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system.

Liu L, Boffa MB, Koschinsky ML.

PLoS One. 2013;8(1):e52287. doi: 10.1371/journal.pone.0052287. Epub 2013 Jan 11.

37.

Apolipoprotein(a) stimulates nuclear translocation of β-catenin: a novel pathogenic mechanism for lipoprotein(a).

Cho T, Romagnuolo R, Scipione C, Boffa MB, Koschinsky ML.

Mol Biol Cell. 2013 Feb;24(3):210-21. doi: 10.1091/mbc.E12-08-0637. Epub 2012 Dec 14.

38.

Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction.

Leibundgut G, Arai K, Orsoni A, Yin H, Scipione C, Miller ER, Koschinsky ML, Chapman MJ, Witztum JL, Tsimikas S.

J Am Coll Cardiol. 2012 Apr 17;59(16):1426-37. doi: 10.1016/j.jacc.2011.12.033.

39.

Identification of tristetraprolin as a factor that modulates the stability of the TAFI transcript through binding to the 3'-untranslated region.

Novakovic D, Kuo AC, Lin JH, Koschinsky ML, Boffa MB.

J Thromb Haemost. 2012 May;10(5):887-94. doi: 10.1111/j.1538-7836.2012.04689.x.

40.

Lipoprotein(a): more interesting than ever after 50 years.

Dubé JB, Boffa MB, Hegele RA, Koschinsky ML.

Curr Opin Lipidol. 2012 Apr;23(2):133-40. doi: 10.1097/MOL.0b013e32835111d8. Review.

PMID:
22327610
41.

Regulation of the mouse gene encoding TAFI by TNFα: role of NFκB binding site.

Garand M, Lin JH, Hill CE, Zagorac B, Koschinsky ML, Boffa MB.

Cytokine. 2012 Mar;57(3):389-97. doi: 10.1016/j.cyto.2011.11.023. Epub 2012 Jan 2.

PMID:
22217421
42.

Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells.

Lin JH, Garand M, Zagorac B, Schadinger SL, Scipione C, Koschinsky ML, Boffa MB.

Thromb Haemost. 2011 Jun;105(6):999-1009. doi: 10.1160/TH10-06-0413. Epub 2011 Apr 20.

PMID:
21505719
43.

Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress.

Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, Tabas I.

Cell Metab. 2010 Nov 3;12(5):467-82. doi: 10.1016/j.cmet.2010.09.010.

44.

The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles.

Arai K, Luke MM, Koschinsky ML, Miller ER, Pullinger CR, Witztum JL, Kane JP, Tsimikas S.

Atherosclerosis. 2010 Apr;209(2):498-503. doi: 10.1016/j.atherosclerosis.2009.09.077. Epub 2009 Oct 12.

PMID:
19880117
45.

Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR.

Lanktree MB, Rajakumar C, Brunt JH, Koschinsky ML, Connelly PW, Hegele RA.

J Lipid Res. 2009 Apr;50(4):768-72. doi: 10.1194/jlr.D800050-JLR200. Epub 2008 Dec 5.

46.

Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation.

Feric NT, Boffa MB, Johnston SM, Koschinsky ML.

J Thromb Haemost. 2008 Dec;6(12):2113-20. doi: 10.1111/j.1538-7836.2008.03183.x. Epub 2008 Oct 4.

47.

Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3.

Liu L, Craig AW, Meldrum HD, Marcovina SM, Elliott BE, Koschinsky ML.

Biochem J. 2009 Mar 1;418(2):325-36. doi: 10.1042/BJ20080744.

PMID:
18821851
48.
49.

Lipoprotein(a) is associated differentially with carotid stenosis, occlusion, and total plaque area.

Klein JH, Hegele RA, Hackam DG, Koschinsky ML, Huff MW, Spence JD.

Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1851-6. doi: 10.1161/ATVBAHA.108.169292. Epub 2008 Jul 3.

PMID:
18599799
50.

Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis.

Boffa MB, Maret D, Hamill JD, Bastajian N, Crainich P, Jenny NS, Tang Z, Macy EM, Tracy RP, Franco RF, Nesheim ME, Koschinsky ML.

Blood. 2008 Jan 1;111(1):183-9. Epub 2007 Sep 12.

Supplemental Content

Loading ...
Support Center